Article info
Original research
Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5–6 years
- Correspondence to Dr Ludovic Tréluyer, Sorbonne Paris-Nord, Inserm, INRAE, CRESS, Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPé, Université Paris Cité, Paris, 75010, France; ludovic.treluyer{at}inserm.fr
Citation
Doxapram for apnoea of prematurity and neurodevelopmental outcomes at age 5–6 years
Publication history
- Received August 3, 2023
- Accepted December 15, 2023
- First published January 16, 2024.
Online issue publication
June 19, 2024
Article Versions
- Previous version (16 January 2024).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.